This transaction builds on a co-development agreement Illumina established with SomaLogic in December 2021 to bring the SomaScan® Proteomics Assay onto Illumina's high-throughput ...

Dr Lal PathLabs has expanded its genomics capabilities by adding Illumina’s NovaSeq X Series to its dedicated genomics division, Genevolve. With the integration of Illumina’s latest technology, DLPL ...

Illumina, Inc. (NASDAQ: ILMN) announced it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven ...

Hi and thank you for releasing this excellent tool! I'm working on promoter variant interpretation in a specific cancer type, and I’d like to tailor PromoterAI more closely to this disease context.

Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach ...